Article
10 Sep 2026
FDA Sharpens Its Pencil And Oversight Tools On Global Clinical Trial Data
RANKINGS
This author falls within the Top 20% for their listed topics and industry categories. Based on Mondaq users readership, this author is ranked as VERY POPULAR in United States
AUTHORS CONTENT
Article
09 Mar 2026
US Senate Probes FDA Bureaucracy vs. Innovation
Article
04 Mar 2026
Stronger Together: NORD's Congressional Briefing On The Heels Of FDA's "Plausible Mechanism" Draft Guidance
Article
15 Jan 2026
Life Sciences Capital Markets: Preparing For Your 2026 IPO
Article
03 Oct 2025
Life Sciences And Medtech Policy Update: Key Things To Know Q4 2025
Article
14 May 2025
Most Favored Nation Drug Pricing Executive Order Resurrects Prior President Trump Policy
Article
28 Apr 2025
Charting A Conditional Approval Pathway For Rare Disease Drugs – A Top Priority For A Revamped FDA?
Article
04 Apr 2025
A Look Ahead In Life Sciences: What We Are Tracking In The Second Quarter Of 2025 And Beyond
Article
28 Feb 2025
Goodwin's 2025 Rare Disease Symposium: Momentum Builds For Addressing Critical Diagnosis And Treatment Gaps
Article
27 Jan 2025
How The Trump Administration Could Reshape Regulation In The Life Sciences Sector
Article
10 Jan 2025
Changes Expected As Trump Administration Continues To Take Shape
Article
07 Nov 2024
New Momentum For A Time-Limited Conditional Approval Pathway For Rare Disease Drugs
Article
03 Oct 2024
A Look Ahead In Life Sciences: What We Are Tracking In The Fourth Quarter Of 2024 And Beyond
Article
25 Jul 2024
Common FDA Bioresearch Monitoring (BIMO) Violations: Updates From FY 2023 To Now
Article
01 Jul 2024
FDA Issues Overdue Draft Guidance On Clinical Trial Diversity Action Plans
Article
10 Jun 2024
Form FDA 483 Response Best Practices Announced By The FDA
Article
04 Jun 2024
Designating A Platform Technology: FDA's Long-Awaited Draft Guidance
Article
09 May 2024
FDA Updates Draft Guidance On Promotional Communications Of Prescription Biologics And Biosimilars
Article
05 Apr 2024
A Look Ahead In Life Sciences: What We Are Tracking In Q2 2024 And Beyond
Article
13 Mar 2024
The BIOSECURE Act And Its Potential Implications
